Lou Chu-Yuan, Wang Yong, Xing Jia-Yuan, Ma Teng, Tao Lei, Wang Xiao-Tang, Wang Run-Sheng
Neuroophthalmic Center, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an 710004, Shaanxi Province, China.
Int J Ophthalmol. 2024 Jun 18;17(6):1073-1078. doi: 10.18240/ijo.2024.06.12. eCollection 2024.
To investigate the short-term efficacy and safety of inebilizumab for neuromyelitis optica spectrum disorders (NMOSD).
A total of 33 patients with NMOSD treated with inebilizumab (Group INB, =15) or rituximab (Group RTX, =18) in addition to high-dose glucocorticoids were included. Both groups underwent hormone shock therapy during the acute phase. Subsequently, Group INB received inebilizumab injections during the remission phase, while Group RTX received rituximab injections. A comparison of aquaporins 4 (AQP4) titer values, peripheral blood B lymphocyte counts, and visual function recovery was conducted before and 8wk after treatment. Additionally, adverse reactions and patient tolerability were analyzed after using inebilizumab treatment regimes.
Following inebilizumab treatment, there was a significantly improvement in the visual acuity of NMOSD patients (<0.05), accompanied by a notable decrease in AQP4 titer values and B lymphocyte ratio (<0.05). Moreover, inebilizumab treatment showed a partial effect in preventing optic nerve atrophy (<0.05). However, there were no significant differences in other therapeutic effects compared to rituximab, which has previously demonstrated substantial therapeutic efficacy (>0.05). Furthermore, inebilizumab exhibited higher safety levels than that of rituximab injections.
The combination of inebilizumab and high-dose glucocorticoids proves to be effective. In comparison to rituximab injections, inebilizumab displays better tolerance and safety. Moreover, it demonstrates a partial effect in preventing optic nerve atrophy. Thus, it stands as an effective method to reduce the disability rates and improve the daily living ability of patients with NMOSD.
探讨依奈利珠单抗治疗视神经脊髓炎谱系障碍（NMOSD）的短期疗效及安全性。
纳入33例接受高剂量糖皮质激素治疗的NMOSD患者，其中15例接受依奈利珠单抗治疗（依奈利珠单抗组），18例接受利妥昔单抗治疗（利妥昔单抗组）。两组在急性期均接受激素冲击治疗。随后，依奈利珠单抗组在缓解期接受依奈利珠单抗注射，而利妥昔单抗组接受利妥昔单抗注射。在治疗前及治疗8周后比较水通道蛋白4（AQP4）滴度值、外周血B淋巴细胞计数及视觉功能恢复情况。此外，分析依奈利珠单抗治疗方案使用后的不良反应及患者耐受性。
依奈利珠单抗治疗后，NMOSD患者视力有显著改善（<0.05），同时AQP4滴度值及B淋巴细胞比例显著降低（<0.05）。此外，依奈利珠单抗治疗在预防视神经萎缩方面有部分效果（<0.05）。然而，与先前已显示出显著治疗效果的利妥昔单抗相比，其他治疗效果无显著差异（>0.05）。此外，依奈利珠单抗的安全性水平高于利妥昔单抗注射。
依奈利珠单抗与高剂量糖皮质激素联合使用被证明是有效的。与利妥昔单抗注射相比，依奈利珠单抗具有更好的耐受性和安全性。此外，它在预防视神经萎缩方面有部分效果。因此，它是降低NMOSD患者残疾率和提高其日常生活能力的有效方法。
